Covaxin Found To Be 77.8% Effective Against Covid And Other Top Stories

  • 54:16
  • Published On: November 12, 2021
Cinema View
Embed
Covaxin phase 3 trial data is finally peer reviewed. The prestigious medical journal Lancet has found the vaccine to be 77.8% effective against symptomatic COVID-19 and 65.2% effective against the delta strain. Also Delhi air pollution is back in the severe category, with wind speeds in single digits, local pollutants are being trapped and mixed with emissions from farm fires.

Related Videos

"A Very Big Source Of Covid Vaccines For World": Bill Gates Praises India
February 29, 2024 3:21
Bharat Biotech's Suchitra Ella On The Lessons From The Covid-19 Pandemic
April 14, 2023 8:47
World's 1st Covid Nasal Vaccine Out On Republic Day
January 26, 2023 8:39
India Gets Its Own Nasal Vaccine, Booster Costs Rs. 800 Per Dose
January 26, 2023 1:18
Covid Nasal Vaccine: Everything You Need To Know
December 27, 2022 1:18
Centre, States To Work In "Collaborative Spirit" To Fight Covid: Health Minister
December 23, 2022 2:57
Nasal Vaccine From Today, Hospital Drills - Preps In Top Gear
December 23, 2022 2:16
Bharat Biotech's Nasal Vaccine Against Covid-19 Cleared For Use
September 06, 2022 2:57
Free Covid Booster Dose For All Adults From Friday For The Next 75 Days
July 13, 2022 1:05
Jabs Begin For 4.7 Crore Children Between 12 And 14
March 16, 2022 3:42
Vaccines For 12-14 Age Group From Wednesday, Boosters For All Above 60
March 14, 2022 1:20
Covaxin Maker Bharat Biotech's Nasal Booster Dose Trials Get Approval
January 28, 2022 2:00
Our Offerings: NDTV
  • मध्य प्रदेश
  • राजस्थान
  • इंडिया
  • मराठी
  • 24X7
Choose Your Destination